Detalles de la búsqueda
1.
The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough.
Cytotherapy
; 23(5): 357-366, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33820700
2.
The INN global nomenclature of biological medicines: A continuous challenge.
Biologicals
; 60: 15-23, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31130314
3.
WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.
Lancet
; 397(10274): 577-578, 2021 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549168
4.
Introduction of a simple guideline to improve neurological assessment in paediatric patients presenting with upper limb fractures.
Emerg Med J
; 33(4): 273-7, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26880750
5.
Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules.
J Virol
; 85(12): 6086-90, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21490098
6.
Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards.
Biologicals
; 40(1): 96-9, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22244521
7.
International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety.
Vaccine
; 40(1): 21-27, 2022 01 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34844820
8.
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Vaccine
; 40(35): 5248-5262, 2022 08 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35715352
9.
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
Vaccine
; 39(22): 3067-3080, 2021 05 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33077299
10.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Vaccine
; 38(49): 7708-7715, 2020 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-32907759
11.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Vaccine
; 38(34): 5556-5561, 2020 07 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32571717
12.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Vaccine
; 38(39): 6184-6189, 2020 09 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32747214
13.
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
Vaccine
; 38(49): 7702-7707, 2020 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33070999
14.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Vaccine
; 38(35): 5734-5739, 2020 07 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-32653276
15.
Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.
Vaccine
; 37(38): 5796-5802, 2019 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30497831
16.
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.
Vaccine X
; 1: 100009, 2019 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31384731
17.
From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.
Nat Rev Microbiol
; 2(10): 842-7, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15378048
18.
Assuring the quality, safety, and efficacy of DNA vaccines.
Methods Mol Med
; 127: 363-74, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16988466
19.
The Ability of a Non-Egg Adapted (Cell-Like) A(H1N1)pdm09 Virus to Egg-Adapt at HA Loci Other than 222 and 223 and Its Effect on the Yield of Viral Protein.
PLoS One
; 11(11): e0166761, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27861557
20.
Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.
Vaccine
; 34(51): 6617-6625, 2016 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27317264